Chronic Low Back Pain – Unmet Need – Detailed, Expanded Analysis – Chronic Low Back Pain (US/EU)

Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, is one of the largest segments of the chronic pain therapy market. Prescription treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), opioid-based analgesics, antiepileptic drugs, and cytokine inhibitors. Although prescription drug-treatment rates in this population are relatively high, opportunity exists for more-potent-yet-safe therapies. This content provides quantitative insight into U.S. and European primary care physicians’ perceptions of key treatment drivers and goals in the management of CLBP, the existing level of unmet need in this indication, and remaining commercial opportunities in this area.


  • What are the treatment drivers and goals for CLBP?
  • What drug attributes are key influencers: which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for CLBP?
  • What are the prevailing areas of unmet need and opportunity in CLBP?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European PCPs / GPs for a hypothetical new CLBP drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European PCPs / GPs fielded in May 2021

Key companies: AstraZeneca, Bristol-Myers Squibb, Endo Pharmaceuticals, Grünenthal, Horizon Therapeutics, Janssen, Pfizer, Purdue.

Key drugs: Celecoxib, fentanyl transdermal patch, lidocaine, 5% transdermal patch, oxycodone CR, pregabalin, tramadol ER, Vimovo (naproxen / esomeprazole).

Table of contents

launch Related Market Assessment Reports